Immunoactivating Peptide P4 Augments Alveolar Macrophage Phagocytosis in Two Diverse Human Populations
Supporting Files
-
Jul 01 2013
-
File Language:
English
Details
-
Alternative Title:Antimicrob Agents Chemother
-
Personal Author:
-
Description:New treatment strategies are urgently needed to overcome early mortality in acute bacterial infections. Previous studies have shown that administration of a novel immunoactivating peptide (P4) alongside passive immunotherapy prevents the onset of septicemia and rescues mice from lethal invasive disease models of pneumococcal pneumonia and sepsis. In this study, using two diverse populations of adult volunteers, we determined whether P4 treatment of human alveolar macrophages would upregulate phagocytic killing of Streptococcus pneumoniae ex vivo. We also measured macrophage intracellular oxidation, cytokine secretion, and surface marker expression following stimulation. Peptide treatment showed enhanced bacterial killing in the absence of nonspecific inflammation, consistent with therapeutic potential. This is the first demonstration of P4 efficacy on ex vivo-derived human lung cells.
-
Subjects:
-
Source:Antimicrob Agents Chemother. 2013; 57(9):4566-4569.
-
Document Type:
-
Funding:
-
Place as Subject:
-
Volume:57
-
Issue:9
-
Collection(s):
-
Main Document Checksum:urn:sha256:f4ec798141be1256734c0d2794e571c964f293accc82831ed02e2ab93c2e3fc9
-
Download URL:
-
File Type:
Supporting Files
File Language:
English
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like
COLLECTION
CDC Public Access